Form 8-K - Current report:
SEC Accession No. 0001193125-26-210825
Filing Date
2026-05-07
Accepted
2026-05-07 10:33:24
Documents
11
Period of Report
2026-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mbx-20260507.htm   iXBRL 8-K 45663
2 EX-99.1 mbx-ex99_1.htm EX-99.1 116655
3 GRAPHIC img258572290_0.gif GRAPHIC 4625
  Complete submission text file 0001193125-26-210825.txt   292998

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mbx-20260507.xsd EX-101.SCH 26956
14 EXTRACTED XBRL INSTANCE DOCUMENT mbx-20260507_htm.xml XML 5116
Mailing Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032
Business Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032 3179893100
MBX Biosciences, Inc. (Filer) CIK: 0001776111 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42272 | Film No.: 26951518
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)